论文部分内容阅读
目的探讨每日2次或3次皮下注射诺和锐30治疗口服降糖药治疗效果不佳的严重T2DM的疗效及低血糖风险。方法选择56例经两种或两种以上口服降糖药治疗后血糖控制不佳的T2DM患者将其分为诺和锐30二针组(A组)和诺和锐30三针组(B组),停用促进胰岛素分泌的口服降糖药,继续联用二甲双胍治疗,观察12周。比较两组的8个时点血糖(三餐前、三餐后、睡前及3∶00)、一日内最大血糖波动幅度、血糖达标率、低血糖发生率和HbA1c。结果 (1)两组治疗后的8个时点血糖和HbA1c水平均较前明显下降(P<0.01)。(2)B组的午餐后血糖及晚餐前血糖低于A组(P<0.01),其他各点血糖和HbA1c比较差异无统计学意义(P>0.05)。(3)B组血糖达标率优于A组,一日内最大血糖波动幅度及低血糖发生率显著低于A组(P<0.05)。结论对于严重T2DM患者每日3次注射诺和锐30较每日2次注射能更好、更平稳地控制血糖并具有更少的低血糖发生率。
Objective To investigate the curative effect and hypoglycemia risk of T2DM with poor response to oral and hypoglycemic agents administered twice or three times a day with Noro Rui 30 subcutaneously. Methods Fifty-six T2DM patients with poor glycemic control after treatment with two or more oral hypoglycemic agents were divided into two groups: Novo Rui-Rui No.2 group (group A) and Novo-Rui30 group (group B) ), Disable the promotion of insulin secretion of oral hypoglycemic agents, continued metformin treatment, observed for 12 weeks. The blood sugar levels (before meals, three meals, before going to bed and at 3:00) were compared between the two groups. The maximum blood glucose level, the rate of blood glucose compliance, the incidence of hypoglycemia and HbA1c in one day were compared. Results (1) The levels of blood glucose and HbA1c in the two groups after treatment were significantly lower than those before (P <0.01). (2) The blood glucose after lunch and the blood sugar before dinner in group B were lower than those in group A (P <0.01). There was no significant difference in blood glucose and HbA1c among other points (P> 0.05). (3) The blood glucose compliance rate in group B was better than that in group A, and the maximal fluctuation of blood glucose and the incidence of hypoglycemia in one day were significantly lower than those in group A (P <0.05). Conclusions NovoRui 30 is better, smoother, and less hypoglycemic with 3 injections of NoroRui 30 twice daily in patients with severe T2DM.